Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients

Tsuyoshi Shirakawa, Michitaka Nakano, Kenta Nio, Shingo Tamura, Masato Komoda, Hozumi Kumagai, Keita Uchino, Keita Odashiro, Shuji Arita, Yoshihiro Shibata, hiroshi ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.

元の言語英語
ページ(範囲)891-898
ページ数8
ジャーナルAnti-Cancer Drugs
27
発行部数9
DOI
出版物ステータス出版済み - 9 1 2016

Fingerprint

Cardiovascular Diseases
Drug Therapy
Neoplasms
Heart Diseases
Venous Thrombosis
Left Ventricular Dysfunction
Hypertension
Disease Progression
Thromboembolism
Venous Thromboembolism
Early Diagnosis
Japan
Thrombosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

これを引用

Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. / Shirakawa, Tsuyoshi; Nakano, Michitaka; Nio, Kenta; Tamura, Shingo; Komoda, Masato; Kumagai, Hozumi; Uchino, Keita; Odashiro, Keita; Arita, Shuji; Shibata, Yoshihiro; ariyama, hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.

:: Anti-Cancer Drugs, 巻 27, 番号 9, 01.09.2016, p. 891-898.

研究成果: ジャーナルへの寄稿記事

Shirakawa, T, Nakano, M, Nio, K, Tamura, S, Komoda, M, Kumagai, H, Uchino, K, Odashiro, K, Arita, S, Shibata, Y, ariyama, H, Kusaba, H, Akashi, K & Baba, E 2016, 'Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients', Anti-Cancer Drugs, 巻. 27, 番号 9, pp. 891-898. https://doi.org/10.1097/CAD.0000000000000392
Shirakawa, Tsuyoshi ; Nakano, Michitaka ; Nio, Kenta ; Tamura, Shingo ; Komoda, Masato ; Kumagai, Hozumi ; Uchino, Keita ; Odashiro, Keita ; Arita, Shuji ; Shibata, Yoshihiro ; ariyama, hiroshi ; Kusaba, Hitoshi ; Akashi, Koichi ; Baba, Eishi. / Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. :: Anti-Cancer Drugs. 2016 ; 巻 27, 番号 9. pp. 891-898.
@article{5bfdfbbd52c246b4ac102e05413fc3e6,
title = "Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients",
abstract = "Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4{\%}), 22 (5.6{\%}), five (1.3{\%}), and 14 (3.5{\%}) cases, respectively. HT (14.5{\%}) and venous thrombosis (5.8{\%}) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1{\%}) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.",
author = "Tsuyoshi Shirakawa and Michitaka Nakano and Kenta Nio and Shingo Tamura and Masato Komoda and Hozumi Kumagai and Keita Uchino and Keita Odashiro and Shuji Arita and Yoshihiro Shibata and hiroshi ariyama and Hitoshi Kusaba and Koichi Akashi and Eishi Baba",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/CAD.0000000000000392",
language = "English",
volume = "27",
pages = "891--898",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients

AU - Shirakawa, Tsuyoshi

AU - Nakano, Michitaka

AU - Nio, Kenta

AU - Tamura, Shingo

AU - Komoda, Masato

AU - Kumagai, Hozumi

AU - Uchino, Keita

AU - Odashiro, Keita

AU - Arita, Shuji

AU - Shibata, Yoshihiro

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.

AB - Appropriate management of cardiovascular diseases (CVDs) related to chemotherapy for solid tumors is important for safe oncologic treatment. However, prediction of the onset and progression of CVDs has not generally been established in Japan. We carried out a retrospective analysis of advanced or recurrent solid tumor patients who received chemotherapies in a single institution. Patient characteristics, chemotherapy regimens, adverse events, CVDs before chemotherapy, and diagnosis of CVDs in association with chemotherapy were assessed. During the period from April 2006 to March 2012, 394 patients were examined. Cardiac diseases (CDs), hypertension (HT), or arterial thrombosis or venous thromboembolism were prevalent in 37 (9.4%), 22 (5.6%), five (1.3%), and 14 (3.5%) cases, respectively. HT (14.5%) and venous thrombosis (5.8%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced a decrease of ejection fraction and early filling/atrial filling (E/A) and E/A tended to decrease before ejection fraction. Ninety (62.1%) of 145 cases showed an increase in the d-dimer (DD) level before chemotherapy, and a further increase in DD level was found when venous thrombosis occurred. Relative risks of the disease progression of HT, CD, and thromboembolism because of chemotherapy were 1.3, 1.9, and 3.6, respectively. A decrease in E/A and an increase in DD were suggested to be valuable for early diagnosis of the respective onsets of left ventricular dysfunction and venous thrombosis related to chemotherapy. We conclude that patients with previous CD tend to have disease progression of CD during chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84973352146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973352146&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000392

DO - 10.1097/CAD.0000000000000392

M3 - Article

VL - 27

SP - 891

EP - 898

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -